Senior User Experience (UX) Architect, Front End Engineer

Overview

The Knowledge Systems Group at Dana-Farber Cancer Institute seeks a Senior User Experience (UX) Architect: Front End Engineer to help build open-source software for precision cancer medicine. Our platforms are focused on mining of cancer genomic data sets, understanding resistance to targeted therapy, and enabling precision medicine initiatives at DFCI.

The Front-End Software Engineer is an exceptional candidate who has extensive web application development experience and a passion for open-source software development.

Required skills

  • Bachelor's degree or Master's Degree in Computer Science, Bioinformatics, Computational Biology or a related field.
  • 3+ years of front-end web application experience.
  • Expert knowledge of Javascript and modern Javascript frameworks, e.g. AngularJS or ReactJS.
  • Expert knowledge of Javascript unit-testing frameworks, e.g. Jasmine or Mocha.
  • Expert knowledge of web and Javascript performance optimization.
  • Data visualization in D3.
  • User interaction design and data visualization.
  • Expert knowledge of HTML and CSS.
  • Portfolio of web application work, e.g. on GitHub or other public sites.
  • Active github/bitbucket account which demonstrates passion and coding abilities.
  • Strong interest in contributing to biological research with clinical applications.
  • Experience in modern software development technologies, including distributed versioning systems, continuous integration, and Agile programming practices.

The candidate must demonstrate outstanding personal initiative and the ability to work effectively as part of a team. Ability to meet deadlines and efficiently multitask is a must.

Desirable skills

Previous experience in bioinformatics is highly desirable, but not required.

How to Apply

Email a short description of your interest with your resume / CV directly to: Ethan Cerami: cerami AT jimmy.harvard.edu.

About Dana-Farber

Located in Boston, Dana-Farber Cancer Institute brings together world renowned clinicians, innovative researchers and dedicated professionals, allies in the common mission of conquering cancer, HIV/AIDS and related diseases. Combining extremely talented people with the best technologies in a genuinely positive environment, we provide compassionate and comprehensive care to patients of all ages; we conduct research that advances treatment; we educate tomorrow's physician/researchers; we reach out to underserved members of our community; and we work with amazing partners, including other Harvard Medical School-affiliated hospitals.

Equal Employment Opportunity

Dana-Farber Cancer Institute is an equal opportunity employer and affirms the right of every qualified applicant to receive consideration for employment without regard to race, color, religion, sex, gender identity or expression, national origin, sexual orientation, genetic information, disability, age, ancestry, military service, protected veteran status, or other groups as protected by law.

Latest News

  • cBioPortal awarded NCI Grant

    Sep 11, 2017

    We are happy to report that the cBioPortal for Cancer Genomics was recently awarded a multi-institutional NCI award!!


    Description: The cBioPortal has become the most widely used tool within the cancer genomics community and is the most highly cited. The public site (cbioportal.org) contains data from more than 20,000 tumor samples, including all data from The Cancer Genome Atlas, and is accessed by more than 25,000 unique users each month. To ensure that this vital resource continues to aid the cancer research community and to keep pace with the rapidly advancing fields of cancer genomics and precision cancer medicine, and the imminent steep increase in the number of profiled tumor samples, we propose to actively sustain and evolve the cBioPortal platform.

    Specifically, we will implement major architectural changes to the cBioPortal software to ensure future scalability and performance, and accelerate new feature development (Aim 1). We will also develop novel analysis tools for drug target discovery in large cancer genomics cohorts, as well as new features for precision cancer medicine, including for clinical trial design and the budding field of immunogenomics (Aim 2). We also plan to build and leverage a vibrant open source software development community to maintain and adapt the software and develop essential new features (Aim 3). Finally, to maximize use in the scientific community, we plan to expand community outreach and education, and create mechanisms for community engagement and feedback (Aim 4).